No abstract

No abstract

No abstract

approach, 59% of AMI patients and 55% of HAL patients maintained efficacy up to 12 months (Kaplan-Meier estimates, log rank 0.58). When time course of mean BPRS total scores of all patients (LOCF) was compared, AMI was superior to HAL from the third month of treatment. On an intent to treat basis, AMI was superior to HAL in total BPRS score (mean change from baseline 17.0 ± 15.8 vs 12.8 ± 15.5, P < 0.01), PANSS Negative subscore (mean change from baseline 7.1 ± 7.7 vs 3.7 ± 7.4, p < 0.01) and quality of life (all dimensions of the QLS). AMI provoked significantly less EPS than HAL and correspondingly less antiparkinson drugs were prescribed to AMI patients. Overall, AMI was safe and efficacious in the long-term treatment of schizophrenia.

No abstract